BioCentury | Dec 2, 2020
Distillery Therapeutics

Metalloprotease MYSM1 identified as protective factor in lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Promoting the expression of the metalloprotease MYSM1 could treat systemic lupus erythematous (SLE). MYSM1 mRNA and protein levels were lower in peripheral blood mononuclear cells (PBMCs) from 14 SLE...
BioCentury | Oct 2, 2020
Distillery Therapeutics

Targeting CXCL1 signaling for HSV-1 encephalitis

...By Claire Quang, Staff Writer DISEASE CATEGORY: Infectious diseaseINDICATION: Encephalitis; herpes simplex virus (HSV)Inhibiting CXCL1 or its...
...infiltration into the brain. Also in the model, systemic CXCR2 knockout or an antibody targeting CXCL1...
...in combination with Keytruda pembrolizumab in Phase II testing to treat solid tumors.TARGET/MARKER/PATHWAY: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis Inhibiting the chemokine receptor CXCR3 or its ligand CXCL9 could treat osteoporosis. In a medaka fish model of RANKL-induced osteoporosis, two CXCR3 inhibitor tool compounds reduced mineralization defects including resorption...
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline

As Gilead continues to expand its manufacturing capabilities for Veklury, the company has moved a step closer to gaining full approval of the therapy in the U.S. for COVID-19. The company announced its NDA submission for...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Jan 18, 2020
Financial News

I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Shares of I-Mab slipped 11% in their first day of trading Friday after the Shanghai-based company priced its IPO on NASDAQ within its proposed range, raising $104 million to fund its cross-border development strategy. The...
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

Efficacy for Btk, FLT3 inhibitor in blood cancers In a pair of posters at the American Society of Hematology (ASH) meeting in Orlando, Aptose Biosciences Inc. (NASDAQ:APTO; TSX:APS) and University of Texas MD Anderson Cancer...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BioCentury | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

Broad influenza protection by human antibodies against neuraminidase A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis identified three human antibodies that could serve...
Items per page:
1 - 10 of 204